Literature DB >> 28639223

Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Toru Kubo1, Hiroaki Kitaoka2.   

Abstract

PURPOSE OF REVIEW: Left ventricular hypertrophy (LVH) is often encountered in clinical practice, and it is a risk factor for cardiac mortality and morbidity. Determination of the etiology and disease severity is important for the management of patients with LVH. The aim of this review is to show the remarkable progress in cardiac imaging and its importance in clinical practice. RECENT
FINDINGS: This review focuses on clinical features and characteristic cardiac imaging in LVH caused by various diseases including hypertension, aortic valve stenosis, hypertrophic cardiomyopathy, and secondary cardiomyopathies. The usefulness of echocardiography as a tool of general versatility including hemodynamic evaluation and the usefulness of cardiac magnetic resonance imaging for assessment of cardiac morphology and myocardial tissue characteristics of relevance for LVH are described. Imaging modalities now have central roles in the differentiation and prognostic assessment of LVH.

Entities:  

Keywords:  Cardiac imaging; Cardiac magnetic resonance; Cardiomyopathy; Echocardiography; Left ventricular hypertrophy

Mesh:

Year:  2017        PMID: 28639223     DOI: 10.1007/s11886-017-0875-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  77 in total

1.  The functional defect in amyloid heart disease. The "stiff heart" syndrome.

Authors:  C Chew; G M Ziady; M J Raphael; C M Oakley
Journal:  Am J Cardiol       Date:  1975-10-06       Impact factor: 2.778

Review 2.  Diagnosis of glycogenosis type II.

Authors:  B Bembi; E Cerini; C Danesino; M A Donati; S Gasperini; L Morandi; O Musumeci; G Parenti; S Ravaglia; F Seidita; A Toscano; A Vianello
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

3.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

Review 4.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

Review 5.  MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside.

Authors:  Jan Bogaert; Iacopo Olivotto
Journal:  Radiology       Date:  2014-11       Impact factor: 11.105

6.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Authors:  Enrica Perugini; Pier Luigi Guidalotti; Fabrizio Salvi; Robin M T Cooke; Cinzia Pettinato; Letizia Riva; Ornella Leone; Mohsen Farsad; Paolo Ciliberti; Letizia Bacchi-Reggiani; Francesco Fallani; Angelo Branzi; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

7.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

Authors:  Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan
Journal:  JACC Cardiovasc Imaging       Date:  2010-02

Review 8.  Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.

Authors:  Sameer Raina; Shelly Y Lensing; Ramez S Nairooz; Naga Venkata K Pothineni; Abdul Hakeem; Sabha Bhatti; Tarun Pandey
Journal:  JACC Cardiovasc Imaging       Date:  2016-08-24

9.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

10.  Natural history of Danon disease.

Authors:  Dana Boucek; Jean Jirikowic; Matthew Taylor
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

View more
  3 in total

1.  Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

Authors:  Zsofia Dohy; Liliana Szabo; Zoltan Pozsonyi; Ibolya Csecs; Attila Toth; Ferenc Imre Suhai; Csilla Czimbalmos; Andrea Szucs; Anna Reka Kiss; David Becker; Bela Merkely; Hajnalka Vago
Journal:  PLoS One       Date:  2022-06-13       Impact factor: 3.752

2.  Detection of intracellular histological abnormalities using cardiac magnetic resonance T1 mapping in patients with Danon disease: a case series.

Authors:  Hideaki Suzuki; Yoshiaki Morita; Ryoko Saito; Shunsuke Tatebe; Tetsuya Niihori; Yoshikatsu Saiki; Satoshi Yasuda; Hiroaki Shimokawa
Journal:  Eur Heart J Case Rep       Date:  2021-05-04

3.  Diagnosis of left ventricular hypertrophy using convolutional neural network.

Authors:  Zini Jian; Xianpei Wang; Jingzhe Zhang; Xinyu Wang; Youbin Deng
Journal:  BMC Med Inform Decis Mak       Date:  2020-09-25       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.